Cabometyx 60 mg, film-coated tablets

( ARTG ) Renal Cell Carcinoma (RCC),CABOMETYX is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC): - in treatment-naïve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy. CABOMETYX in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,Hepatocellular​‍​​​​​‍​‍‍‍‍​‍‍ Carcinoma (HCC),CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.,Differentiated Thyroid Carcinoma (DTC),CABOMETYX is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed during or after prior VEGFR-targeted therapy and who are radioactive iodine (RAI) refractory or ineligible.,Neuroendocrine Tumours (NET),CABOMETYX is indicated for the treatment of adult patients with locally advanced/unresectable or metastatic, well-differentiated extra-pancreatic (epNET) or pancreatic (pNET) neuroendocrine tumours who have progressed on at least one prior systemic therapy other than a somatostatin analogue.